Bloomberg -- Johnson & Johnson’s antipsychotic medicine Risperdal Consta, its third-best-selling drug, fared no better than less expensive treatments at keeping schizophrenia patients out of the hospital, U.S. researchers said. Patients on Risperdal Consta, a twice-monthly injection, ended up in the hospital 39 percent of the time during the three-year analysis, about the same as those who took other drugs as a daily pill, a study released yesterday in the New England Journal of Medicine said.
